22 completed, 2 terminated, 1 recruiting. 25 Phase 2, 6 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 22, Terminated 2, Recruiting 1 |
| Phase 1 | 6 | Completed 6 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
Follow BOTOX®: new trials by email Literature Review of BOTOX® trials Research Report on BOTOX®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults Recombinant Botulinum Toxin Type A for injection (YY001), BOTOX®, Placebo - Upper Limb Spasticity | Phase 2 / Phase 3 | Recruiting | Chongqing Claruvis Pharmaceutical Co., Ltd. | 254 | 2024-09-14 | 2026-01-22 |
| A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines JHM03, BOTOX®, Placebo - Moderate to Severe Glabellar Lines | Phase 1 / Phase 2 | Completed | JHM BioPharma (Tonghua) Co. , Ltd. | 190 | 2024-01-19 | 2025-04-02 |
| The Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines PROTOXIN, Botox® - Glabellar Frown Lines | Phase 1 / Phase 2 | Completed | Protox Inc. | 60 | 2020-12-10 | 2021-08-10 |
| BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence OnabotulinumtoxinA, Normal saline - Masseter Muscle Prominence | Phase 2 | Completed | Allergan | 150 | 2019-05-16 | 2021-04-28 |
| Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects ATGC-100, Botox® - Moderate to Severe Glabellar Lines | Phase 1 / Phase 2 | Completed | EuBiologics Co.,Ltd | 60 | 2019-04-19 | 2021-03-23 |
| Efficacy of an Intra-articular Injection of Botulinum Toxin A Associated With Splinting for Base-of-thumb Osteoarthritis botulinum toxin A, saline - Base-of-thumb Osteoarthritis | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 60 | 2018-11-29 | 2025-09-05 |
| BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence OnabotulinumtoxinA and Hydrogel admixture, Placebo and Hydrogel admixture - Urinary Incontinence, Overactive Bladder With Urinary Incontinence | Phase 2 | Completed | Allergan | 383 | 2017-10-04 | 2021-08-13 |
| BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis onabotulinumtoxinA, Normal Saline - Osteoarthritis | Phase 2 | Completed | Allergan | 176 | 2014-10-01 | 2017-05-31 |
| Treatment With Xeomin Versus Botox in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy Xeomin, Botox® - Cerebral Palsy, Spastic Paraplegia and Hemiparesis | Phase 2 | Completed | Merz Pharmaceuticals GmbH | 64 | 2014-07-01 | 2017-01-26 |
| OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females onabotulinumtoxinA, Normal Saline - Depressive Disorder, Major | Phase 2 | Completed | Allergan | 258 | 2014-04-22 | 2017-12-19 |
| Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy botulinum toxin Type A, Normal saline - Masseter Muscle Hypertrophy | Phase 2 | Completed | Allergan | 187 | 2014-01-20 | 2019-05-28 |
| A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation OnabotulinumtoxinA, Normal Saline - Premature Ejaculation | Phase 2 | Terminated | Allergan | 59 | 2013-08-07 | 2018-10-18 |
| Safety and Efficacy Study of Botulinum Toxin Type A as Treatment for Osteoarthritis Knee Pain botulinum toxin Type A, Normal Saline - Osteoarthritis | Phase 1 / Phase 2 | Completed | Allergan | 121 | 2012-01-01 | 2014-08-07 |
| A Two-Part Study of BOTOX® Therapy for Ischemic Digits onabotulinum toxin type-A - Raynaud's Disease | Phase 2 | Completed | Southern Illinois University | 48 | 2011-05-01 | 2019-01-08 |
| Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia botulinum toxin Type A, Normal saline - Benign Prostatic Hyperplasia | Phase 2 | Completed | Allergan | 315 | 2010-08-01 | 2019-05-03 |
| H-22411: BOTOX® for Peyronie's Disease 100 units of Botulinum Toxin Type A, Preservative free normal saline, 100 units Botulinum Toxin A - Peyronie's Disease | Phase 2 | Completed | Mohit Khera | 12 | 2009-08-07 | 2024-04-08 |
| A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia Botulinum Toxin Type A, Placebo (saline) - Benign Prostatic Hyperplasia | Phase 1 / Phase 2 | Completed | Allergan | 61 | 2009-08-01 | 2013-09-30 |
| The Impact of Botox® During Robotic Rehabilitation of the Wrist Following Stroke Botox®, saline solution - Stroke | Phase 1 / Phase 2 | Completed | New York Presbyterian Hospital | 12 | 2009-06-01 | 2011-04-26 |
| Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia botulinum toxin type A, botulinum toxin type A Formulation 2, Normal Saline - Cervical Dystonia | Phase 2 | Completed | Allergan | 242 | 2007-12-01 | 2016-01-05 |
| Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder Normal saline (Placebo); botulinum toxin Type A (200U), botulinum toxin Type A (50U); botulinum toxin Type A (200U), botulinum toxin Type A (100U); botulinum toxin Type A (200U) - Overactive Bladder | Phase 2 | Terminated | Allergan | 74 | 2007-12-01 | 2015-10-02 |
Showing 20 of 25. Sign in to see all of them.
Stroke (4) · Muscle Spasticity (3) · Prostatic Hyperplasia (3) · Osteoarthritis (2) · Paresis (2) · Urinary Bladder, Overactive (2) · Urinary Incontinence (2) · Cerebral Palsy (1) · Depressive Disorder, Major (1) · Ischemia (1) · Masticatory Muscles, Hypertrophy of (1) · Motor Neuron Disease (1) · Paraplegia (1) · Penile Induration (1) · Premature Ejaculation (1)
Allergan (16) · Assistance Publique - Hôpitaux de Paris (1) · Chongqing Claruvis Pharmaceutical Co., Ltd. (1) · EuBiologics Co.,Ltd (1) · JHM BioPharma (Tonghua) Co. , Ltd. (1) · Merz Pharmaceuticals GmbH (1) · Mohit Khera (1) · New York Presbyterian Hospital (1) · Protox Inc. (1) · Southern Illinois University (1)
United States (15) · Canada (7) · Czechia (5) · Germany (4) · Poland (4) · South Korea (4) · United Kingdom (4) · France (3) · Taiwan (3) · Australia (2) · China (2) · Denmark (2) · Hungary (2) · India (2) · Philippines (2)
Beomjoon Kim (1) · Beta Bowen (1) · Daniel Radecki (1) · Michael W Neumeister, MD (1) · Mohit Khera, MD, MBA (1) · Shobhal Patel (1) · Tanya Brandstetter (1) · Till Geib (1) · Xinhua Wan (1)
PMID 22464310, PMID 23098762, PMID 29753118, PMID 29961037, PMID 31609787, PMID 38294016
2014 (1)